Carbenicillin Indanyl

Carbenicillin Indanyl

SCHEMBL33857

CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(=O)Oc3ccc4c(c3)CCC4)c3ccccc3)C(=O)N2[C@H]1C(=O)O

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Carbenicillin Indanyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.57
▸ RECQL P46063 3/20 0.57
▸ TDP1 Q9NUW8 2/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ POLB P06746 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ TEK Q02763 1/20 0.57
▸ SLC15A2 Q16348 1/20 0.57
▸ LMNA P02545 4/20 0.56
▸ TSHR P16473 1/20 0.56
▸ PTGS1 P23219 2/20 0.55
▸ CCKBR P32239 1/20 0.53
▸ CA1 P00915 6/20 0.51
▸ CA2 P00918 6/20 0.51
▸ HRH1 P35367 1/20 0.50
▸ SLC22A8 Q8TCC7 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ RARB P10826 1/20 0.49
▸ RARG P13631 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbenicillin Indanyl SCHEMBL33855 1.00 KDM4E (0.57) KDM4ERECQLTDP1MEN1KMT2A
Carbenicillin Indanyl SCHEMBL4936924 1.00 KDM4E (0.57) KDM4ERECQLTDP1MEN1KMT2A
Carbenicillin Indanyl SCHEMBL29592774 1.00 KDM4E (0.57) KDM4ERECQLTDP1MEN1KMT2A
Carbenicillin Indanyl SCHEMBL11309244 1.00 KDM4E (0.57) KDM4ERECQLTDP1MEN1KMT2A
Carbenicillin Indanyl SCHEMBL10741454 1.00 KDM4E (0.57) KDM4ERECQLTDP1MEN1KMT2A
Carbenicillin Indanyl SCHEMBL22818119 0.99 KDM4E (0.56) KDM4ERECQLTDP1MEN1KMT2A
Carbenicillin Indanyl SCHEMBL954017 0.99 KDM4E (0.56) KDM4ERECQLTDP1MEN1KMT2A
Carbenicillin Indanyl SCHEMBL11311104 0.99 KDM4E (0.56) KDM4ERECQLTDP1MEN1KMT2A
Carbenicillin Indanyl SCHEMBL15668574 0.98 PTGS1 (0.56) KDM4ERECQLTDP1MEN1KMT2A
Carbenicillin Indanyl SCHEMBL1736359 0.97 PTGS1 (0.55) KDM4ERECQLTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2458 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 — — US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 — — US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 — — US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 — — EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 — — EP claimed
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 — — US claimed
WO-2024239281-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 — — WO claimed
WO-2024240173-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 — — WO claimed
EP-4426727-A2 SPECIFIC CONJUGATION OF AN ANTIBODY Hangzhou Dac Biotech Co., Ltd. (CN) 2024-09-11 — — EP claimed
EP-4426741-A1 BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE Hangzhou DAC Biotech Co., Ltd. (CN) 2024-09-11 — — EP claimed
EP-0138523-B1 PENICILLIN DERIVATIVES AND PROCESS FOR PREPARING THE SAME (11111) TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1987-08-19 — — EP claimed
US-4668514-A Penicillin derivatives TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1987-05-26 — — US claimed
US-4562073-A BETA-LACTAMASE INHIBITORS TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1985-12-31 — — US claimed
US-4529592-A Substituted in position 2 with a (4,5-diester-1,2,3-triazol-3-yl)alkyl group TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) 1985-07-16 — — US claimed
EP-0138523-A1 Penicillin derivatives and process for preparing the same (11111) TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1985-04-24 — — EP claimed
US-4381307-A Soft tertiary amine esters of bio-affecting carboxylic acids MERCK & CO., INC. (US) 1983-04-26 — — US claimed
US-4376767-A ANTIBIOTICS AND PHARMACEUTICALS MERCK & CO., INC. (US) 1983-03-15 — — US claimed
EP-0055870-A1 Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same MERCK & CO. INC. (US) 1982-07-14 — — EP claimed
EP-0051278-A1 Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same MERCK & CO. INC. (US) 1982-05-12 — — EP claimed
EP-0050965-A1 Beta-lactamase inhibitory composition Takeda Chemical Industries, Ltd. (JP) 1982-05-05 — — EP claimed
Send feedback